|
|
Article: Cubist Pharmaceuticals Selects ACS Dobfar as Single Source API Supplier.
- Article from:
- Business Wire
- Article date:
- November 30, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that it has selected ACS Dobfar S.p.A. as the single source supplier of Active Pharmaceutical Ingredient (API) for the IV antibiotic, CUBICIN(R) (daptomycin for injection). ACS's substantial fermentation and purification plant capacity enables it to meet all anticipated needs for CUBICIN API, and Cubist will therefore no longer require a second supplier for this portion of the CUBICIN supply chain. ACS's substantial plant capacity will also, over time, contribute to further improvement in CUBICIN cost-of-goods-sold.
"ACS provides us with high quality material for CUBICIN today and has ...
Related newspaper, magazine, and journal articles:
|
|
Article: CUBICIN Approved for S. aureus Bloodstream Infections in ...
Business Wire;
August 1, 2007 ;
700+ words
... ... NASDAQ: CBST) today announced that CUBICIN([R])(daptomycin for injection ... structure infections (cSSSI) and SAB/RIE. CUBICIN was previously approved in Taiwan (in ... received by Kuhnil Pharmaceutical Corp. (CUBICIN marketing partner for South Korea) and ...
|
|